Anonymous
Guest
Anonymous
Guest
Clearly, Lilly's problem with Oraflex has done damage to its earnings and the value of its stock. The company, a diversified manufacturer of agricultural chemicals, medical instruments and cosmetics, as well as pharmaceuticals, earned $375.5 million, or $4.93 a share, in 1981, up 10 percent from a net of $342 million, or $4.52 a share, in the year earlier. Immediately after its suspension of the drug, Lilly estimated that its earnings in the second half of 1982 would be reduced 15 cents a share, or $11.4 million.